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Nimotuzumab is a humanized monoclonal antibody (mAb), a potential anticancer 
against epidermal growth factor receptor (EGFR)overexpressed by glioma, head and 
neck, lung, ovarium, and colon cancers. The combination of its use with both 
external and internal beam radiotherapies showed improvement of the therapeutic 
effect. However, the high molecular weight slows its uptake on tumor cells.                      
In a recent development, nimotuzumab has been fragmented and then labeled using 
diagnostic and therapeutic radionuclides, such as gallium-68, yttrium-90, lutetium-
177, and holmium-166. In that preparation, nimotuzumab is often conditioned in 
various environments with variations of pH, temperature and the presence of other 
compounds. In this research, molecular dynamics (MD) simulation have been 
carried out to study the CDRs conformational change of  nimotuzumab due to the 
effect of temperature, and also steered molecular dynamics (SMD) simulation to 
study the stability of nimotuzumab domain as a result of external forces.                
The simulations were performed using the Not Just Another Molecular Dynamics 
(NAMD) program package and the analysis was performed with the Visual 
Molecular Dynamics (VMD) program package. Based on the stability analysis of 
each residue on the heavy chain, the active site (CDR3 region) that is at residues 
numbered 98 (Tryptophan) and 99 (Phenylalanine) has the highest conformational 
changes. On the light chain, the change occurs at residues numbered 1 (Aspartat), 
127 (Serin), and 186 (Tyrosine); and that none of that residues is part of active site 
or CDRs region of the light chain. The SMD simulation was carried out by fixing 
the N-terminal end of the heavy chain and applying external forces to the C-terminal 
end. The pulling was set at a constant velocity of 0.5 Å/ps. The force peak arising at 
the beginning of the unfolding process is 1226 pN. This force was allegedly caused 
by the rupture of hydrogen bonds between the heavy chain residue VAL211 
(Valine) and the heavy chain residue TYR194 (Tyrosine). 
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INTRODUCTION 
Cancer represents one of the leading causes of 
death in the world and lung cancer is the most 
common cause of cancer-related death worldwide, 
                                                 
 Corresponding author. 
   E-mail address: humani@batan.go.id 
in which non-small cell lung cancer reaches 75% of 
all lung cancer cases [1]. According to WHO, in 
2008 there were 7.5 million deaths caused by 
cancer, 70% of which occurred in developing 
countries. Because of the high number of deaths 
caused by cancer, various studies of clinical 
treatments of cancer therapy have been conducted. 
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However, the widely and commonly used therapies 
by means of surgery, radiotherapy, and 
chemotherapy have still not provided very 
satisfactory results, particularly in addition to                
some adverse side effects to the cancer patients                
[2]. Much ongoing research is directed to                  
targeted therapy using biomolecules, such as 
monoclonal antibodies, which are able to 
specifically interact with target molecules,                     
such as receptors and antigens, which are 
overexpressed by cancer cells. The mechanism                 
of action of monoclonal antibodies is usually                    
preceded by their interaction through                             
non-covalent bonds with the receptors                               
on the surface of cancer cell membranes in                        
the body. It appears that the cell surface                               
of non-small cell lung cancer overexpress                     
Epidermal Growth Factor Receptor (EGFR),                     
as well as breast cancer, glioma, colon cancer,                 
and head and neck cancer [3,4]. The EGFR                   
belongs to the family of tyrosine kinase                          
receptors (RTKs). Overexpression of EGFR                      
is often associated with cancer malignancy                      
and plays a significant role in tumor development 
and progression, including cell proliferation, 
regulation of apoptotic cell death, angiogenesis,   
and metastatic spread [5]. Therefore, one                      
of the methods used for the cancer therapy                          
is to inhibit the effects of EGFR activation,                      
with the aim of blocking tumor growth and 
invasion, using either specific antibodies                   
directed against its ligand-binding domains or               
small molecules inhibiting its tyrosine kinase 
activity [6-9]. 
Nimotuzumab or also called h-R3 is a 
humanized monoclonal antibody specific to EGFR 
and is one of the alternative cancer therapeutic 
agents. Although nimotuzumab is not included in 
the 12 antibodies which have been approved                
by the Food and Drug Administration (FDA), its use 
would be interesting because of the absence of side 
effects such as skin rashes [3,10]. This is in contrast 
to the use of other of monoclonal antibodies 
targeting EGFR which cause skin rashes in every 
use [11,12]. 
Over the past several years, metal-
radionuclide-labeled nimotuzumab has been 
developed as target-specific radiopharmaceuticals 
that is commonly called radioimmunotherapeutic 
agents or radioimmunodiagnostic agents if                   
labeled with therapeutic or diagnostic radionuclides, 
respectively, using a bifunctional chelating                   
agent (BFCA). The BFCA could form both                
stable metal radionuclide complexes and 
immunoconjugates with antibodies and peptides.                
In general, the process of conjugation and                        
labeling of monoclonal antibodies can be                     
carried out in various conditions such as                           
pH adjustment and temperature changes [13].                     
This condition would certainly impact the                    
three-dimensional structure of nimotuzumab as a 
protein. Accordingly, it is necessary to 
computationally observe the effects prior                           
to both labeling with radionuclides and conjugation 
with nimotuzumab. Ideally, both labeling                         
and conjugation processes will not much affect                   
the conformation of nimotuzumab, particularly                   
the residues in the CDR that play a main role                      
in the binding to the receptors. 
The purpose of this study was to 
computationally investigate (i) the effect of 
temperature changes on the three dimensional 
conformation of the nimotuzumab F(ab)                     
fragment, especially the residues on the 
Complementarity Determining Regions                   
(CDRs), (ii) the residues that play                                    
role in maintaining the stability of the structure of 
the nimotuzumab F(ab) fragment, and                               
(iii) the minimal force to trigger the                                   
unfolding process of the nimotuzumab                             
F(ab) fragment including a bond that establishes               
the stability of the unfolding process,                       
using molecular dynamics simulations. This 
computational study is very important to                        
predict the behavior of the CDRs of nimotuzumab 
or their fragments prior to binding affinity                    
studies of them to EGFR using either molecular 
docking or radioligand binding assay. 
 
 
EXPERIMENTAL METHODS 
The program packages used to perform 
molecular dynamics simulations and steered 
molecular dynamics simulations (SMD) were Not 
Just Another Molecular Dynamics (NAMD) 
program [14], and the Visual Molecular Dynamics 
(VMD) program for the preparation of the input 
files [15], respectively. The NAMD and VMD 
programs are distributed for free and available at 
http://www.ks.uiuc.edu/Research. 
A Pdb file (3GKW) of the nimotuzumab 
F(ab) fragment that contains the atomic coordinates 
and velocities of atoms in the system was obtained 
from the protein data bank in http://www.pdb.org. 
The fragment used in this study has two chains, 
namely the heavy chain and the light chain.                 
The active regions or the so-called Complementarity 
Determining Regions (CDRs) are divided into six 
active regions, namely CDR1, CDR2, and CDR3 
which are located in the heavy chain,and CDR1, 
CDR2, and CDR3 in the light chain (see Fig. 1).  
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Fig. 1. Complementarity Determining Regions (CDRs) of a 
monoclonal antibody IgG. Taken from www.piercenet.com on 
September 15th, 2013. 
NAMD was run using a CHARMM                   
force field and TIP3 solvent. The first step of 
simulation studies was the preparation of          
molecules, which includes reading pdb files                     
and psf files, creation of boundary conditions, 
solvation and ionization. The next step                           
was the energy minimization to reach a state                     
with a minimum local energy, heating/                    
cooling gradually until the desired temperature,               
and equilibration until the energy converges                         
to a certain value, then followed by the                      
molecular dynamics and steered molecular 
dynamics (SMD) simulations. In this                             
study, molecular dynamics simulations were run 
using the timestep of 2 fs, the cut-off of 20 Å,                 
and a switching function at 10 Å at the temperatures 
of 277 K, 310 K, 350 K and 373 K, respectively. 
The temperatures of 277 K and 310 K                      
represent conditions at which the nimotuzumab 
F(ab) fragment undergoes a conjugation                         
reaction with a BFCA and labeling                                  
with a radionuclide, respectively. Steered                    
molecular dynamics simulation (SMD) was 
performed by introducing external force at the                 
C-terminal end of the nimotuzumab                               
F(ab) fragment’s heavy chain, whereas                           
the N-terminal end was fixed. Simulations                   
were performed using two protocols, i.e. with 
constant velocity and with constant force. In the first 
one, pulling was done at a constant velocity                         
of 0.5 Å/ps and 1 Å/ps. Force obtained in the first 
protocol then will be used as a reference force for 
the second protocol. 
The simulation results were analyzed using 
VMD program that focused on the three-
dimensional conformational changes of the 
nimotuzumab F(ab) fragment. The analysis was 
based on the change in the value of the root mean 
square displacement (RMSD) or root mean square 
deviation of the atoms after the simulation process 
compared with the initial position (reference). 
RMSD is defined as: 
 
  
N
=i
)r(i,t)r(i,
N
=RMSD
1
2
0
1
 (1) 
 
where N is the number of atoms in the protein 
and r (i, t) is the position of the i-th atom at time t.  
 
 
RESULTS AND DISCUSSION 
 
Molecular dynamics simulation of 
nimotuzumab in various temperatures 
The difference of temperature effect on                    
the nimotuzumab F(ab) fragment structure                        
can be described by the Root Mean                          
Square Displacement (RMSD) values of Cα                     
atoms that refer changes in the conformation                     
of each residue. Analysis of RMSD during                         
the 900 ps simulation at a temperature of 277 K,                         
310 K, 350 K, and 373 K, obtained RMSD                    
values of 2.37, 2.50, 2.46 and 2.53, respectively 
(Fig. 2). 
 
 
Fig. 2. Graph of RMSD versus time simulated at a various 
temperatures. 
 
 The RMSD values for all temperatures show 
that the change in temperature affects the structure 
of a protein. However, the RMSD analysis of Cα 
atoms only describes the global stability of the 
nimotuzumab F(ab) fragment structure. Therefore, 
in addition to global stability, the local one is 
necessary to be studied, especially to the stability of 
the active regions of a protein. Figure 3 depicted 
RMSD analysis for each residue of the heavy chain 
(see also Fig. 4).  
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Fig. 3. Graph of RMSD per residue of the heavy chain at 
temperatures of 277 K , 310 K , 350 K and 373 K. 
 
Increasing the temperature has a considerable 
effect, especially toward residues numbered 27 
(tyrosine), 28 (threonine), 83 (arginine), 84 (serine), 
98 (tryptophan), 99 (phenylalanine), 183 
(threonine), 184 (valine), and 185 (proline) as well. 
Table 1 shows that residues numbered 98 
(tryptophan) and 99 (phenylalanine) have the 
highest RMSD value (bold numbered in the table). 
Both of these residues are in the active region of the 
CDR3 region of the heavy chain of the 
nimotuzumab F(ab) fragment, while in the CDR1 
and CDR2 regions, conformational changes                 
are lower. 
 
Table 1. RMSD of CDRs at heavy chains 
 
 
Talavera et al. [10] reported that a residue 
tryptophan H103 plays an important role in 
nimotuzumab function as a monoclonal antibody. 
The RMSD values of tryptophan H103 (H refers to 
heavy chain) during the simulation period at 
temperatures of 277 K, 310 K, 350 K and 373 K in 
our study are 2.59, 3.42, 3.01 and 3.30, respectively. 
This implies that the conformation of H103 will be 
affected by temperature changes. Analysis of 
conformational changes was also carried out for the 
residues of H103, H98 and H99 at temperatures of 
277 K and 310 K as depicted in Fig. 4.                     
The conformation of the residue H98 at 277 K was 
more exposed to solvent than at 310 K. On the 
contrary, conformation of the residue H99 was more 
opened at temperatures of 310 K compared to that of 
277 K. The conformation differences of residues of 
H98 and H99 at temperatures of 277 K and 310 K 
are very interesting to be considered due to the 
conjugation process of the nimotuzumab F(ab) 
fragment which is commonly performed at a 
temperature of 277 K. The probability of the 
conjugation reaction will be high at the residue H98 
because of its smaller steric hindrance and larger 
solvent-accessible surface at 277 K. This will be 
slightly different at the body temperature of 310 K 
due to slight changes of H98 conformation that 
leads to the different effectiveness of nimotuzumab 
as an anti-EGFR drug. 
 
  
 
Fig. 4. Three dimensional conformation of residues of  H98, 
H99, and H103 in nimotuzumab structure, left is at a 
temperature of 277 K, right is at 310 K. 
 
On the other hand, residue H103 has a higher 
steric hindrance at temperature 310 K than that of 
277 K due to the interaction between residue H103 
and residues of 41-44 from the nimotuzumab F(ab) 
fragment’s light chain (see Fig. 4). Table 2 shows 
the effect of temperature on each residue.                   
The numbers in bold in the Table 2 are the residues 
that have the highest RMSD value of each peak as 
shown also in Fig. 3. The grey line represents the 
residues with the highest RMSD that tend toward a 
different pattern. It appears that the highest 
conformational changes at temperatures of 310 K, 
350 K and 373 K were identified as residues of                   
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99 and 185. However, at a temperature of 277 K, the 
highest conformational changes were residues of 98 
and 184, one unit less than the changes experienced 
by the residues of 99 and 185.  
 
Table 2. Residues of high RMSD at several temperatures 
 
Residue 
Number 
Temperature 
277 K 310 K 350 K 373 K 
27 13.689 16.06 13.157 11.156 
28 13.392 17.155 12.902 11.698 
83 8.9024 8.5199 9.2354 10.116 
84 10.776 9.6806 9.6638 10.818 
98 11.596 8.9294 13.125 11.078 
99 9.7221 12.739 16.876 14.745 
183 13.623 9.6149 12.746 11.711 
184 13.664 11.379 12.736 12.601 
185 13.584 12.944 13.724 13.22 
 
The stability of three-dimensional 
conformations of the active site (CDRs) needs to be 
maintained in order for protein to still function 
normally. Figure 5 shows the RMSD per residue of 
the light chain of the nimotuzumab F(ab) fragment 
at temperatures of 277 K, 310 K, 350 K, and 373 K. 
It appears that the effect of temperature  changes on 
the light chain of the nimotuzumab F(ab) fragment 
did not result in much change to the structure. 
However, significant changes occur in the residues 
numbered 1 (aspartate), 127 (serine), and 186 
(tyrosine) as shown in Fig. 5. It can be inferred that 
all residues in the CDR1 (28-34), CDR2 (50-56), 
and CDR3 (89-97) have very small RMSD values 
(see Fig. 5). 
 
 
Fig. 5. RMSD per residue of nimotuzumab light chain at 
temperatures of 277 K, 310 K, 350 K, and 373 K. 
 
In general, RMSD analysis shows that 
temperature changes more strongly affect the 
conformation of the nimotuzumab F(ab) fragment’s 
heavy chain than that of the light chain. 
Steered Molecular Dynamics (SMD) 
simulations  
The purpose of SMD simulations is to 
determine both the structural stability of the 
nimotuzumab F(ab) fragment that experiences 
external force and the bonds that affect that stability. 
SMD simulations were directed at observing the 
occurrence of the unfolding process of each domain 
in the nimotuzumab F(ab) fragment (VL, VH, CL 
and CH1). The first protocol of SMD simulation 
was performed by pulling the nimotuzumab               
F(ab) fragment with constant velocity of 0.5 Å/ps 
and 1 Å/ps at the end of the C-terminal of the heavy 
chain, whereas the N-terminal end of the heavy 
chain was fixed. 
The SMD simulation applied for the heavy 
chain results in the force peak of 1226 pN for the 
pulling velocity of 0.5 Å/ps and 1688 pN for the 
pulling velocity 1 Å/ps, at 14 ps (Fig. 6). Analysis 
of hydrogen bonds in this period indicates that 
ruptures and formations of hydrogen bonds occur. 
The total number of hydrogen bonds that occur 
during the 900 ps simulated was about 699 bonds. 
 
 
Fig. 6. Graph of force versus time in the first 260 ps SMD 
simulation. The blue color is a graph obtained at a constant 
velocity of 0.5 Å/ps, while the red color is a graph obtained at a 
constant velocity of 1 Å/ps. 
 
At the initial condition, prior the SMD 
simulation, there were 94 hydrogen bonds present in 
the structure of the nimotuzumab F(ab) fragment. 
Hydrogen bonds occur between the residues of the 
heavy chain and the light chain, and inter-residues 
of the heavy chain and the light chain. Hydrogen 
bonds between residues of the heavy chain and the 
light chain play a significant role in the formation of 
a quaternary structure of the nimotuzumab F(ab) 
fragment, which is the bond that unites the heavy 
chain polypeptide with a light chain polypeptide. 
The two chains are linked by seven hydrogen bonds 
as shown in Table 3.  
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Table 3. Hydrogen Bonds Between the Heavy Chain (SegU) 
and the Light Chain (SegV) 
 
No 
Donor Acceptor Bond 
Length 
(Å) Residue Atom Residue Atom 
1 
SegU-GLN95-
Side 
HE22 
SegV-TYR36-
Side 
OH 1.9 
2 
SegU-GLN95-
Side 
HE21 
SegV-ASP34-
Side 
OD2 1.83 
3 
SegV-GLN38-
Side 
HE21 
SegU-GLN39-
Side 
OE1 1.76 
4 
SegU-HSE164-
Side 
HE2 
SegV-ASP167-
Side 
OD1 1.78 
5 
SegV-THR164-
Side 
HG1 
SegU-HSE164-
Side 
ND1 1.97 
6 
SegV-SER162-
Side 
HG1 
SegU-PRO167-
Main 
O 1.77 
7 
SegV-GLN160-
Side 
HE21 
SegU-LEU170-
Main 
O 1.91 
 
For the purpose of simulations, a hydrogen 
bond is defined to occur if the distance between the 
donor atom and acceptor atom is at most 3 Å and 
the maximum angle formed between these two 
atoms is 20°. Figure 7 (a) shows the relationship 
between distances of donor and acceptor atoms and 
simulation time. 
 
 
(a) 
 
(b) 
 
Fig. 7. (a) The distance between donor and acceptor atoms 
during the simulation period. A fine line is the distance between 
the two atoms, while the dashed line is the distance of the two 
atoms that still allows the hydrogen bonds, (b) Rendering of the 
structure before SMD simulations. Seen the 14 residues forming 
hydrogen bonds connecting the heavy chain and the light chain, 
with licorice imaging techniques, while the whole structure of 
nimotuzumab displayed with new cartoon imaging techniques. 
Figure is created using VMD 1.9 [15]. 
It appears that the seven hydrogen                    
bonds linking the heavy chain and the                           
light chain undergo rupture (distance > 3 Å)                           
at the beginning of the simulation. The bond 
between residue GLN39 of the heavy                              
chain and residue GLN38 of the light chain                   
would break first at the simulation time                             
of 3 ps, followed by another six hydrogen                          
bonds (Table 4). The breaking of the hydrogen 
bonds will contribute to the onset of the                           
force peak (Fig. 6) and also can trigger a                          
process of the nimotuzumab F(ab) fragment 
unfolding. 
 
Table 4. The rupture of seven hydrogen bonds between the 
heavy chain and the light   chain. The first bond breaking occurs 
from top to bottom 
 
No 
Donor 
Residue  
Acceptor 
Residue 
Displacem
ent (Å) 
Time 
(ps) 
1 
SegV-GLN38-
Side 
SegU-GLN39-
Side 
1.76-3.10 3 
2 
SegU-HSE164-
Side 
SegV-ASP167-
Side 
1.78-3.76 28 
3 
SegV-THR164-
Side 
SegU-HSE164-
Side 
1.97-3.09 34 
4 
SegV-SER162-
Side 
SegU-PRO167-
Main 
1.77-3.12 43 
5 
SegU-GLN95-
Side 
SegV-TYR36-
Side 
1.9-4.06 44 
6 
SegU-GLN95-
Side 
SegV-ASP34-Side 1.83-3.46 50 
7 
SegV-GLN160-
Side 
SegU-LEU170-
Main 
1.91-3.43 300 
 
Application of force to the C-terminal                 
end of the heavy chain, which is the region                        
close to the CH1 domain of the nimotuzumab                
F(ab) fragment, will be used for analyzing                        
the hydrogen bonds in this domain.                                 
From three-dimensional structure analysis,                             
the CH1 domain is formed by the heavy                           
chain residues numbered 116-212. Accordingly, 
there are 27 hydrogen bonds in the CH1                       
domain, in which the bonds between                             
residue LYS143 and ASP144 including                        
between residue GLY162 and THR183                               
will break up first at the simulation time                               
of 7 ps. This bond breaking is followed                              
by the ruptures of the bond between                               
residue TYR194 and VAL211 at 14 ps                              
and, afterward, the bond between residue                           
GLU148 and TYR145 at 55 ps (see Table 5).  
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Table 5. The rupture of some of hydrogen bonds between 
residues of the heavy chain. The first bond breaking occurs 
from top to bottom 
 
No 
Donor Acceptor 
Distance 
(Å) 
Time 
(ps) 
Residue Atom Residue Atom 
1 
LYS143-
Side 
HZ2 
ASP144-
Side 
OD1 
1,77-
3,64 
7 
2 
THR183-
Main 
HN 
GLY162-
Main 
O  
1,94-
3,08 
7 
3 
VAL211-
Main 
HN 
TYR194-
Main 
O 
1,79-
3,13 
14 
4 
TYR145-
Side 
HH 
GLU148-
Side 
OE1 
1,67-
3,85 
55 
 
By comparing Fig. 6 and Table 5, it is 
apparent that there is a correlation between the force 
peak and the breaking of the hydrogen bonds. At the 
time of 14 ps simulation with a constant velocity of 
0.5 Å/ps, the first force peak is at 1226 pN. At the 
same time, there is a breaking of the hydrogen bond 
between the residues VAL211 and TYR194. It can 
be concluded that the force peak of 1226 pN arises 
from the rupture of a hydrogen bond between these 
two residues. It can be presumed that the hydrogen 
bond between VAL211 and TYR194 residues is one 
of the bonds determines the stability of CH1 
domain. After this peak is reached, the force falls 
back during the simulation, simultaneously along 
with the other hydrogen bond breakings. At the end 
of the simulation, the graph rises sharply until the 
unfolding process is complete (Fig. 8). 
 
 
Fig. 8. Graph of force versus time for 900 ps SMD simulation. 
 
Figure 8 shows that after 500 ps of the SMD 
simulation, the force increases sharply reaching a 
value of 25.000 pN at the simulation time of 900 ps. 
This may be due to the quaternary structure of the 
nimotuzumab F(ab) fragment consisting of two 
polypeptide chains of heavy and light chains. Due to 
the force applied to the Cα atoms of the                         
C-terminal end of the heavy chain, the                      
force works directly on the heavy chain,                    
rather than on the light chain. Until the                        
end of the simulation, only the heavy                         
chain is undergoing a process of unfolding,             
whereas the light chain is still in the                          
folded state, thus it results in a huge                           
force which could cause the unfolding process                    
in the light chain (Fig. 9). On the other                     
hand, the results obtained from the SMD                 
simulation with the working force at the                        
Cα atoms of the C-terminal end of the                        
light chain, indicate that only the light                        
chain is undergoing a process of unfolding,            
whereas the heavy chain is still in the                            
folded state (Fig. 10). Supposing an analogy                  
to the contrary process, the possibility of                      
the folding process of the nimotuzumab                     
F(ab) fragment is initiated with folding                          
on each heavy and light chain, in which                        
then both chains are joined together to                        
form a quaternary structure of the nimotuzumab 
F(ab) fragment. 
 
   
 
 
 
Fig. 9. The process of unfolding and breaking of hydrogen 
bonds during the SMD simulation with a pulling velocity of 0.5 
Å/ps. The blue color is a heavy chain and the red color is a light 
chain. (a) For 0 ps, there is a hydrogen bond between the 
TYR194 and VAL21 residues as shown by the green dashed 
lines, (b) For 7 ps, the hydrogen bond starts to  rupture, (c) At 
14 ps simulation, there is no presence of hydrogen bond, (d) At 
900 ps simulation, the heavy chain has undergone a process of 
unfolding, whereas the light chain is still in a folded state.  
 
 
 
Fig. 10. The results of the SMD simulation for the light chain. 
The blue color is the heavy chain and the red color is the light 
chain. At 900 ps simulation, the light chain has undergone a 
process of unfolding, whereas the heavy chain is still in                
a folded state. 
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The force peak of 1226 pN in the                 
process of unfolding the nimotuzumab                              
F(ab) fragment delineates a protein with a            
molecular weight of 50 kDa that is relatively                 
small when compared with the actual                           
molecular weight. According to Hui Lu                               
and Klaus Schulten [16], the force needed                           
to pull and lead the unfolding of a protein                          
depends on the architecture of the proteins. 
The protein architecture takes account                         
of three-dimensional conformation of secondary 
structure, the position of β-strand structure                        
(parallel or not parallel), and the                               
presence or absence of a hydrogen bonds                           
between the N-terminal and C-terminal,                          
either directly or indirectly. These will                              
affect the magnitude of force that is                             
required to trigger the protein unfolding                      
process. 
There are three classes of proteins                        
according to Hui Lu and Klaus Schulten                           
[16], i.e. class Ia, class Ib and class II.                                  
In the structure of class Ia, hydrogen bonds                         
connect directly between the N-terminal                           
and C-terminal, which is laid out in                                    
the same direction. It would provide                                    
the best protection against the unfolding                         
process because it requires breaking a larger         
number of hydrogen bonds simultaneously                           
to unfold the protein molecule, so it will                              
necessary need a large force. In the structure                     
of class Ib, hydrogen bonds do not connect directly 
between the N-terminal and C-terminal.                         
The hydrogen bond breakings will occur in a wider 
place, so it will be a gradual increase in force. 
Whereas in structure of class II, hydrogen bonds 
connect directly between the N-terminal and                   
C-terminal, which is laid out in opposite directions. 
The force required to trigger the process of 
unfolding is smaller and not enough to cause 
extreme peak. Hydrogen bonds will rupture one by 
one so it does not need a great force. Because of the 
SMD simulations of the nimotuzumab F(ab) 
fragment were done with work force at the                     
C-terminal end of the heavy chain as part of a region 
of the CH1 domain, whereas the N-terminal end was 
fixed, the CH1 domain has an architecture-like 
structure of class Ib as indicated from the results of 
structural analysis using VMD 1.9 program [15].       
In this structure, there are no hydrogen bonds 
connecting directly between the N-terminal strand 
and C-terminal strand. However, the hydrogen 
bonds occurs between the terminal strand and non-
terminal strand. The position of the N-terminal and 
C-terminal of CH1 domain is also located in the 
opposite direction (see Fig. 11).  
 
 
Fig. 11. Architecture of the CH1 domain resembles classes Ib 
made by Hui Lu and Klaus Schulten [16]. The green color 
depicts the N-terminal and C-terminal strands. This figure is 
created using VMD 1.9 [15]. 
 
In addition to the SMD simulations performed 
at a constant velocity of 0.5 Å/ps, simulations                
were also carried out with the pulling velocity                     
of 1 Å/ps and resulted in force peak of 1688 pN                
at 14 ps. This force is greater than that of a                 
velocity of 0.5 Å/ps. Therefore, the force                     
required to cause the unfolding process                               
of the nimotuzumab F(ab) fragment using atomic 
force microscopy (AFM) is predicted to be smaller, 
because of the pulling velocity used by SMD 
simulations is larger than the AFM. In SMD 
simulation with a pulling velocity of 0.5 Å/ps, a 
force peak of 1226 pN was obtained. In addition, 
from SMD simulations at a constant velocity of               
0.5 Å/ps, the rupture of the hydrogen bond between 
the residue TYR194 and residue VAL211 occur 
after 14 ps simulation or after a 7-Å lengthening. 
 
 
 
 
Fig. 12. Graph of N-terminal and C-terminal distance                
versus time 
 
Further, from the SMD simulation using 
second protocol with contstant force, it as obtained 
that the rupture of the hydrogen bond between these 
two residues, TYR194 and VAL211, occurred at 
484 ps, 29 ps and 1 ps for the working forces of              
200 pN, 300 pN and 800 pN, respectively (Fig. 12). 
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It can be concluded that in the actual experiment 
(AFM), the force required to trigger the unfolding 
process of CH1 domain of the heavy chain of the 
nimotuzumab F(ab) fragment ranges from 300 pN  
to 800 pN. 
 
 
CONCLUSION 
We have performed molecular dynamics 
simulations of the nimotuzumab F(ab) fragment for 
various temperatures and steered molecular 
dynamics (SMD) simulation at a constant velocity 
of 0.5 Å/ps. It can be concluded that temperature 
changes have a considerable effects on the 
conformation of both heavy and light chains of              
the nimotuzumab F(ab) fragment, especially at 
residues numbered 27 (tyrosine), 28 (threonine), 83 
(arginine), 84 (serine), 98 (tryptophan), 99 
(phenylalanine), 183 (threonine), 184 (valine), and 
185 (proline) for the heavy chain and 1 (aspartate), 
127 (serine), and 186 (tyrosine) for the light chain, 
respectively. The residues numbered 98 and 99 are 
part of CDR3, however, the conformational changes 
of residues in the CDR1 and CDR2 regions are 
much lower. Based on the SMD simulations, the 
hydrogen bond between residue VAL211 and 
TYR194 determines the stability of CH1 domain of 
the nimotuzumab F(ab) fragment.  
For further research, it is advisable to  
perform molecular dynamics simulations of 
immunoconjugates of radiolabeled nimotuzumab 
and their interactions with EGFR in blood plasma at 
body temperature. 
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